HU0203985D0 - Use of a pharmaceutical composition for alleviating side effect of a disease - Google Patents
Use of a pharmaceutical composition for alleviating side effect of a diseaseInfo
- Publication number
- HU0203985D0 HU0203985D0 HU0203985A HUP0203985A HU0203985D0 HU 0203985 D0 HU0203985 D0 HU 0203985D0 HU 0203985 A HU0203985 A HU 0203985A HU P0203985 A HUP0203985 A HU P0203985A HU 0203985 D0 HU0203985 D0 HU 0203985D0
- Authority
- HU
- Hungary
- Prior art keywords
- disease
- pharmaceutical composition
- side effect
- alleviating side
- alleviating
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0203985A HUP0203985A3 (en) | 2002-11-18 | 2002-11-18 | Use of a pharmaceutical composition for alleviating side effect |
AU2003278514A AU2003278514A1 (en) | 2002-11-18 | 2003-11-07 | Use of a thiazolidinedione for the reduction of side effects of chemotherapy |
PCT/IB2003/005127 WO2004045611A1 (en) | 2002-11-18 | 2003-11-07 | Use of a thiazolidinedione for the reduction of side effects of chemotherapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0203985A HUP0203985A3 (en) | 2002-11-18 | 2002-11-18 | Use of a pharmaceutical composition for alleviating side effect |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0203985D0 true HU0203985D0 (en) | 2003-01-28 |
HUP0203985A2 HUP0203985A2 (en) | 2004-07-28 |
HUP0203985A3 HUP0203985A3 (en) | 2005-04-28 |
Family
ID=89980932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203985A HUP0203985A3 (en) | 2002-11-18 | 2002-11-18 | Use of a pharmaceutical composition for alleviating side effect |
Country Status (2)
Country | Link |
---|---|
HU (1) | HUP0203985A3 (en) |
WO (1) | WO2004045611A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2150255A4 (en) | 2007-05-10 | 2011-10-05 | Glaxosmithkline Llc | Quinoxaline derivatives as p13 kinase inhibitors |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999048529A1 (en) * | 1998-03-20 | 1999-09-30 | Warner-Lambert Company | Retinoid-glitazone combinations |
WO2000018234A1 (en) * | 1998-09-29 | 2000-04-06 | Board Of Regents, The University Of Texas System | Thiazolidenediones alone or in combination with other therapeutic agents for tumor therapy |
WO2002080913A1 (en) * | 2001-04-06 | 2002-10-17 | F. Hoffmann-La Roche Ag | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth |
-
2002
- 2002-11-18 HU HU0203985A patent/HUP0203985A3/en unknown
-
2003
- 2003-11-07 WO PCT/IB2003/005127 patent/WO2004045611A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0203985A3 (en) | 2005-04-28 |
WO2004045611A1 (en) | 2004-06-03 |
WO2004045611A8 (en) | 2004-08-26 |
HUP0203985A2 (en) | 2004-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2394894B (en) | New use for pharmaceutical composition | |
HK1085131A1 (en) | Solid drug for oral use | |
AU2003244650A8 (en) | Medicinal compounds | |
GB0225540D0 (en) | Medicinal compounds | |
GB0204719D0 (en) | Medicinal compounds | |
GB0225535D0 (en) | Medicinal compounds | |
GB0220730D0 (en) | Medicinal compounds | |
GB0225030D0 (en) | Medicinal compounds | |
IL176519A0 (en) | Directly compressible pharmaceutical composition for the oral administration of cci-779 | |
IL213806A0 (en) | Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions | |
HK1072194A1 (en) | Oral dosage form for controlled drug release | |
GB2392618B (en) | Compositions for therapeutic use | |
HK1102021A1 (en) | Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative | |
HU0203985D0 (en) | Use of a pharmaceutical composition for alleviating side effect of a disease | |
ZA200603126B (en) | Pharmaceutical compositions for therapeutic use | |
AU2003222571A8 (en) | Novel therapeutic application for a composition | |
IL147496A (en) | Preparation of a therapeutic composition | |
GB0226830D0 (en) | Composition for use as a medicament | |
SI1701698T1 (en) | Directly compressible pharmaceutical composition for the oral admimistration of cci-779 | |
GB0224502D0 (en) | Medicinal compounds | |
GB0225023D0 (en) | Medicinal compounds | |
GB0225025D0 (en) | Medicinal compounds | |
GB0225538D0 (en) | Medicinal compounds | |
GB0225024D0 (en) | Medicinal compounds | |
GB0224498D0 (en) | Medicinal compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |